Drugs / Human Rabies Immunoglobulins
Human Rabies Immunoglobulins
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT04478084 | Aug 2020 → Mar 2022 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04594551 Background | Oct 2020 → Jun 2021 | — | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human rabies immunoglobulins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04478084 ↗ |
| Modality | Protein / enzyme biologic | “Human rabies immunoglobulins (HRIG)” NCT04478084 ↗ |
| Route | Intramuscular | “Route of administration: intramuscular” NCT04478084 ↗ |